467 results match your criteria: "Institute of Clinical Neuroimmunology[Affiliation]"

Dissection of complement and Fc-receptor-mediated pathomechanisms of autoantibodies to myelin oligodendrocyte glycoprotein.

Proc Natl Acad Sci U S A

March 2023

Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians-Universität München, 82152 Planegg-Martinsried, Germany.

Article Synopsis
  • Researchers have identified autoantibodies against myelin oligodendrocyte glycoprotein (MOG) as a key factor in a new disease called MOG-antibody-associated disease (MOGAD), which resembles multiple sclerosis.
  • The study explores how these MOG-specific antibodies damage the nervous system, focusing on the roles of complement proteins and Fc-receptors.
  • Findings show that both mechanisms contribute equally to nerve damage, while the activation of certain immune cells in the brain depends specifically on FcR interactions, suggesting potential targets for new treatments.
View Article and Find Full Text PDF

Chimeric antigen receptor T cells (CAR-T cells) have emerged as a powerful treatment option for individuals with B cell malignancies but have yet to achieve success in treating acute myeloid leukemia (AML) due to a lack of safe targets. Here we leveraged an atlas of publicly available RNA-sequencing data of over 500,000 single cells from 15 individuals with AML and tissue from 9 healthy individuals for prediction of target antigens that are expressed on malignant cells but lacking on healthy cells, including T cells. Aided by this high-resolution, single-cell expression approach, we computationally identify colony-stimulating factor 1 receptor and cluster of differentiation 86 as targets for CAR-T cell therapy in AML.

View Article and Find Full Text PDF
Article Synopsis
  • Optic neuritis (ON) often signals the onset of multiple sclerosis (MS) and other related disorders, with high-dose corticosteroids recommended for treatment but not adequately studied regarding timing and patient antibodies.
  • The Acute Optic Neuritis Network (ACON) aims to investigate how the timing of corticosteroid treatment affects visual outcomes 6 months post-ON onset by enrolling patients who present within 30 days of initial symptoms.
  • The study will collect extensive data on various ON subtypes and factors like visual acuity, imaging results, and patient-reported outcomes from 28 hospitals globally, targeting a recruitment of 200 patients across different ON classifications.
View Article and Find Full Text PDF

Objectives: Reactive gliosis is a common pathological hallmark of CNS pathology resulting from neurodegeneration and neuroinflammation. In this study we investigate the capability of a novel monoamine oxidase B (MAO-B) PET ligand to monitor reactive astrogliosis in a transgenic mouse model of Alzheimer`s disease (AD). Furthermore, we performed a pilot study in patients with a range of neurodegenerative and neuroinflammatory conditions.

View Article and Find Full Text PDF

It remains unresolved whether central nervous system involvement in treated classical galactosemia (CG) is a progressive neurodegenerative process. This study aimed to investigate retinal neuroaxonal degeneration in CG as a surrogate of brain pathology. Global peripapillary retinal nerve fibre layer (GpRNFL) and combined ganglion cell and inner plexiform layer (GCIPL) were analysed in 11 CG patients and 60 controls (HC) using spectral-domain optical coherence tomography.

View Article and Find Full Text PDF

Antibodies Against Glutamic Acid Decarboxylase 65 Are Locally Produced in the CSF and Arise During Affinity Maturation.

Neurol Neuroimmunol Neuroinflamm

May 2023

From the Institute of Clinical Neuroimmunology (M.B., K.E., E.B., S.W., S.M., A.T., A.F.-H., T.K., M.K., E.M., F.S.T.), University Hospital, Ludwig-Maximilians-Universität Munich; Biomedical Center (BMC) (M.B., K.E., E.B., S.W., S.M., A.T., A.F.-H., T.K., M.K., E.M., F.S.T.), Medical Faculty, Ludwig-Maximilians-Universität Munich, Martinsried; Graduate School of Systemic Neurosciences Ludwig-Maximilians-Universität Munich (M.B., K.E.); Munich Cluster for Systems Neurology (SyNergy) (E.B., M.K., F.S.T.); Innate Immunity Unit (A.T.), Institut Pasteur, Inserm U1223, Paris, France; Université de Paris (A.T.), Sorbonne Paris Cité, France; Institute of Laboratory Medicine (P.E.), University Hospital, LMU Munich; Institute of Clinical and Molecular Virology (P.S.), University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg; and Department of Neurology (J.L.), University Hospital Ulm, Germany.

Background And Objectives: Antibodies (Abs) against the cytoplasmic protein glutamic acid decarboxylase 65 (GAD65) are detected in patients with neurologic syndromes together referred to as GAD65-Ab spectrum disorders. The response of some of these patients to plasma exchange or immunoglobulins indicates that GAD65-Abs could contribute to disease pathogenesis at least at some stages of disease. However, the involvement of GAD65-reactive B cells in the CNS is incompletely understood.

View Article and Find Full Text PDF

Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders.

J Neurol Neurosurg Psychiatry

July 2023

Moorfield's Eye Hospital, The National Hospital for Neurology and Neurosurgery, Queen Square Institute of Neurology, University College London, London, UK.

Article Synopsis
  • The study investigates the effectiveness of intereye differences (IED) in optical coherence tomography (OCT) parameters to diagnose optic neuritis (ON) in patients with aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders (AQP4+NMOSD).
  • It compares OCT data from AQP4+NMOSD patients who had unilateral ON more than six months prior with healthy controls and other AQP4+NMOSD patients without ON, measuring both absolute and percentage differences in retinal thickness.
  • The findings show high accuracy for using IED metrics in diagnosing ON in AQP4+NMOSD, indicating that these OCT parameters could improve diagnostic criteria for this condition.
View Article and Find Full Text PDF

Background: There is limited and inconsistent information on the prevalence of cognitive impairment in neuromyelitis optica spectrum disorders (NMOSD).

Objective: To assess cognitive performance and changes over time in NMOSD.

Methods: This study included data from 217 aquaporin-4-IgG-seropositive (80%) and double-seronegative NMOSD patients.

View Article and Find Full Text PDF

Background: Data on the humoral vaccine response in patients on anti-interleukin-6 (IL-6) receptor therapy remain scarce.

Objective: The main objective of our study was to investigate the humoral response after vaccination against SARS-CoV-2 in neuromyelitis optica spectrum disorder (NMOSD)/myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) patients treated with anti-IL-6 receptor therapy. Secondarily, we analyzed relapse activity timely associated with vaccination.

View Article and Find Full Text PDF

Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis.

Neurol Neuroimmunol Neuroinflamm

March 2023

From the Institute of Clinical Neuroimmunology (S.H., E.O., H.K.W., A.V., I.M., F.T., T.K., E.M., S.M.), Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität München; Graduate School of Systemic Neurosciences (S.H.), Ludwig-Maximilians-Universität München, Germany; Department of Neurology (A.V.), Koc University School of Medicine; Department of Neuroscience (V.Y., E.T.), Aziz Sancar Institute of Experimental Medicine, Istanbul University; Department of Neurology (R.T.), Haydarpasa Numune Education and Research Hospital, Istanbul, Türkiye; Core Facility Bioinformatics (T.S.), Biomedical Center, Ludwig-Maximilians-Universität München, Germany; Munich Cluster for Systems Neurology (SyNergy) (F.T.), Germany.

Article Synopsis
  • Ocrelizumab, an anti-CD20 treatment, effectively reduces B cell populations in multiple sclerosis (MS) patients but has complex effects on immune systems, particularly related to the BAFF-APRIL system.* -
  • The research analyzed immune cell changes over 2.5 years, revealing that ocrelizumab led to increased BAFF levels and decreased free soluble receptors like sTACI in both serum and cerebrospinal fluid (CSF).* -
  • The reduction of sTACI, which normally acts as a decoy for APRIL, may enhance APRIL's activity, potentially affecting the regulation of immune responses in MS and promoting certain plasma cell types.*
View Article and Find Full Text PDF

B cells contribute to the pathogenesis of both cellular- and humoral-mediated central nervous system (CNS) inflammatory diseases through a variety of mechanisms. In such conditions, B cells may enter the CNS parenchyma and contribute to local tissue destruction. It remains unexplored, however, how infection and autoimmunity drive transcriptional phenotypes, repertoire features, and antibody functionality.

View Article and Find Full Text PDF

Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study.

Neurol Neuroimmunol Neuroinflamm

March 2023

From the Department of Neurology (M.W.H., F.B., D.T., S.G., C.T.), Hannover Medical School, Germany; Department of Neurology (I.A., T.P., K.H., I.K.), St. Josef Hospital, Ruhr University Bochum, Germany; Department of Neurology (L.K.), University of Münster, Germany; Department of Neurology and Institute of Neuroimmunology and MS (INIMS) (V.H., J.-P.S.), University Medical Center Hamburg-Eppendorf, Germany; Aix-Marseille Univ (J.-P.S.), CNRS, CRMBM, UMR 7339, Marseille Cedex, France; APHM (J.-P.S.), Hopital de La Timone, CEMEREM, Marseille, France; Department of Neurology (C.W., Y.G.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Department of Neurology (T.E.), Kliniken Südostbayern-Klinikum Traunstein, Germany; Department of Neurology (F.L.), University Medical Center of the Johannes Gutenberg University Mainz, Germany; Hannover Medical School (P.B.), Department of Diagnostic and Interventional Neuroradiology, Germany; Department of Neurology (A.-S.L.), German Diagnostic Clinic, DKD Helios Clinic Wiesbaden, Germany; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke, Berg, Germany; Department of Neurology (P.S.R.), Medical University of Vienna, Austria; Experimental and Clinical Research Center (F.P., J.B.-S., A.D.), a Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Germany; Department of Neurology (F.P., J.B.-S., A.D.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Experimental and Clinical Research Center, Germany; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) (F.P., J.B.-S., A.D.), Berlin, Germany; Department of Neurology (F.T.B.), University of Leipzig, Germany; Department of Neurology (R.P.), University of Essen, Germany; Department of Neurology (A.W.), Herford Hospital, Germany; Institute of Clinical Neuroimmunology (H.P., T.K.), LMU Hospital, Ludwig-Maximilians Universität München, Germany; Department of Neurology (M.P., M.K.), Alfried-Krupp-Krankenhaus Essen, Germany; Department of Neurology (M.K., P.A., O.A., M.R.), Medical Faculty, Heinrich Heine University Düsseldorf, Germany; Department of Neurology (M.R.), Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich Heine University Düsseldorf, Germany; Department of Neurology (M.S.), University of Ulm, Germany; Department of Neurology (K.G., A.B.), School of Medicine, Technical University Munich, Klinikum Rechts der Isar, Germany; and Molecular Neuroimmunology Group (S.J., B.W.), Department of Neurology, University of Heidelberg, Germany.

Background And Objectives: To evaluate the effects of the coronavirus disease 2019 (COVID-19) pandemic on the life of patients with neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated diseases (MOGAD).

Methods: This multicenter, cross-sectional study included data of 187 patients recruited from 19 different German and Austrian Neuromyelitis Optica Study Group (NEMOS) centers between July 2021 and March 2022. The effects of the pandemic on immunotherapeutic treatment and access to care, the possible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the potential effect of vaccination against SARS-CoV-2 on disease incidence and relapse risk were assessed using a patient questionnaire.

View Article and Find Full Text PDF

Humoral signatures of MOG-antibody-associated disease track with age and disease activity.

Cell Rep Med

February 2023

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, WWU, Münster 48149, Germany. Electronic address:

Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated disease (MOGAD) is an inflammatory demyelinating disease of the CNS. Although MOG is encephalitogenic in different mammalian species, the mechanisms by which human MOG-specific Abs contribute to MOGAD are poorly understood. Here, we use a systems-level approach combined with high-dimensional characterization of Ab-associated immune features to deeply profile humoral immune responses in 123 patients with MOGAD.

View Article and Find Full Text PDF
Article Synopsis
  • High levels of antibodies against glutamic acid decarboxylase (GAD-abs) are linked to various autoimmune neurological syndromes, while the significance of low serum levels is still debated.
  • A study analyzed data from 101 patients suspected of having GAD-ab-associated neurological issues, revealing that most presented with conditions like epilepsy and cerebellar ataxia but had mixed outcomes with immunotherapy.
  • The research found that low GAD-ab serum levels didn't significantly affect clinical characteristics or outcomes, suggesting that detecting unmatched oligoclonal bands in the cerebrospinal fluid may be more important than GAD-ab levels.
View Article and Find Full Text PDF

Functional recovery following incomplete spinal cord injury (SCI) depends on the rewiring of motor circuits during which supraspinal connections form new contacts onto spinal relay neurons. We have recently identified a critical role of the presynaptic organizer FGF22 for the formation of new synapses in the remodeling spinal cord. Here, we now explore whether and how targeted overexpression of FGF22 can be used to mitigate the severe functional consequences of SCI.

View Article and Find Full Text PDF

Functional recovery after incomplete spinal cord injury depends on the effective rewiring of neuronal circuits. Here, we show that selective chemogenetic activation of either corticospinal projection neurons or intraspinal relay neurons alone led to anatomically restricted plasticity and little functional recovery. In contrast, coordinated stimulation of both supraspinal centers and spinal relay stations resulted in marked and circuit-specific enhancement of neuronal rewiring, shortened EMG latencies, and improved locomotor recovery.

View Article and Find Full Text PDF

Neuroinflammation after stroke is characterized by the activation of resident microglia and the invasion of circulating leukocytes into the brain. Although lymphocytes infiltrate the brain in small number, they have been consistently demonstrated to be the most potent leukocyte subpopulation contributing to secondary inflammatory brain injury. However, the exact mechanism of how this minimal number of lymphocytes can profoundly affect stroke outcome is still largely elusive.

View Article and Find Full Text PDF

Decreasing the activation of pathology-activated microglia is crucial to prevent chronic inflammation and tissue scarring. In this study, we used a stab wound injury model in zebrafish and identified an injury-induced microglial state characterized by the accumulation of lipid droplets and TAR DNA-binding protein of 43 kDa (TDP-43) condensates. Granulin-mediated clearance of both lipid droplets and TDP-43 condensates was necessary and sufficient to promote the return of microglia back to the basal state and achieve scarless regeneration.

View Article and Find Full Text PDF

Autoimmune neuropathy associated with antibodies against pan-neurofascin is a new subtype of nodo-paranodopathy. It is relevant because it is associated with high morbidity and mortality. Affected patients often require intensive care unit treatment for several months, and data on the reversibility and long-term prognosis are limited.

View Article and Find Full Text PDF

Background And Purpose: Brain pseudoatrophy has been shown to play a pivotal role in the interpretation of brain atrophy measures during the first year of disease-modifying therapy in multiple sclerosis. Whether pseudoatrophy also affects the spinal cord remains unclear. The aim of this study was to analyze the extent of pseudoatrophy in the upper spinal cord during the first 2 years after therapy initiation and compare this to the brain.

View Article and Find Full Text PDF

Seizure Semiology in Antibody-Associated Autoimmune Encephalitis.

Neurol Neuroimmunol Neuroinflamm

November 2022

From the Hans-Berger Department of Neurology (T.K., C.G., Albrecht Kunze), University Hospital Jena; Department of Neurology (Marie Madlener, Michael Malter), Faculty of Medicine and University Hospital Cologne, University of Cologne; Department of Neurology (K.A.), University of Regensburg; Department of Epileptology (Krankenhaus Mara) (C.G.B.), Bielefeld University, Medical School, Campus Bielefeld-Bethel; Department of Psychiatry and Psychotherapy (Y.B.), Asklepios Hospital Teupitz; Department of Neurology (K.D.), University of Würzburg; Department of Neurology (A.F.), Hospital Lüneburg; Department of Neurology (S.T.G.), University Hospital Erlangen; Department of Neurology (G.R.), Klinikum Dortmund; Department of Neuro-pediatrics (M.H.), RWTH University Hospital Aachen; Department of Neurology (R.H.), Carl-Thiem Klinikum Cottbus; Department of Neurology (K.H.), University of Bochum; Institut für Neuroimmunologie und Multiple Sklerose (M.K.), Zentrum für Molekulare Neurobiologie Hamburg, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Department of Neurology (C.K.), Klinikum Osnabrück; Department of Neurology (P.K.), University of Magdeburg; Department of Neurology (Andrea Kraft), Martha-Maria Hospital Halle; Department of Neurology (J.L.), University of Ulm; Department of Neurology (T.M., M.R.), Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich-Heine-University Düsseldorf, Germany; Department of Neurology (A.P.), Klinikum Hirslanden, Zürich; Department of Neurology (F.v.P., M.S.), University of Greifswald; Department of Neurology and Experimental Neurology (H.P.), Charité Berlin, and German Center for Neurodegenerative Diseases (DZNE); Department of Neurology (S.R., N.M.), University of Freiburg; Department of Neurology (M.R.), Medical Faculty, Heinrich-Heine-University Düsseldorf, Germany; Department of Neuropediatrics (K.R.), Vestische Kinder-und Jugendklinik Datteln; Department of Neurology (I.S.), University Hospital Giessen and Marburg, Giessen; Department of Neurology (J.S.), Asklepios Hospital Nord, Hamburg; Department of Neurology (P.S.), Hospital Hubertusburg, Wermsdorf; Department of Neurology (K.-W.S.), University Hospital Hannover; Department of Epileptology (R.S.), University Hospital Bonn; Department of Neurology (S.C.T.), RWTH University Hospital Aachen; Institute of Clinical Neuroimmunology (F.T.), University Hospital, Ludwig-Maximilians-Universität Munich, Germany and Biomedical Center (BMC), Medical Faculty, Ludwig-Maximilians-Universität Munich, Martinsried, Germany; Department of Neurology (F.T.B.), University of Leipzig; Department of Neurology (C.U.), Hospital Ludwigshafen; Institute of Clinical Chemistry (K.-P.W.), University Hospital Schleswig-Holstein, Kiel/Lübeck, Germany; Department of Neurology (B.W.), University of Heidelberg; Department of Neurology (S.M.), University Hospital, Technische Universität Dresden; Universitätsklinikum Knappschaftskrankenhaus Bochum Langendreer (S.M.), Klinik für Neurologie; Department of Neurology (U.Z.), University of Rostock; Department of Neurology (F.L.), Christian-Albrechts-University Kiel; Department of Neurology with Institute of Translational Neurology (N.M.), University Hospital Muenster; and Department of Neurology (Albrecht Kunze), Zentralklinik Bad Berka, Germany.

Article Synopsis
  • - The study evaluates seizure characteristics in patients with antibody-associated autoimmune encephalitis (ab + AE) focusing on the three most common antibodies: NMDAR, LGI1, and GAD, involving 320 patients across multiple centers in Germany.
  • - Seizures were prevalent in these patients, with frequencies of 60% in NMDAR+, 78% in LGI1+, and 65% in GAD+, and certain types of seizures such as faciobrachial dystonic seizures and status epilepticus presented uniquely or more frequently in specific antibody groups.
  • - The findings suggest that seizure types can help in diagnosis, with distinct patterns observed among different antibodies, indicating that NMDAR+ patients tend to have
View Article and Find Full Text PDF

To pave the way for healthy aging in early treated phenylketonuria (ETPKU) patients, a better understanding of the neurological course in this population is needed, requiring easy accessible biomarkers to monitor neurological disease progression in large cohorts. The objective of this pilot study was to investigate the potential of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) as blood biomarkers to indicate changes of the central nervous system in ETPKU. In this single-center cross-sectional study, GFAP and NfL concentrations in serum were quantified using the Simoa multiplex technology in 56 ETPKU patients aged 6-36 years and 16 age matched healthy controls.

View Article and Find Full Text PDF